Table 1:
Tumor histopathology, grade and receptor status proliferation rate stratified by RCB class.
| RCB 0 (pCR) | RCB 1 | RCB 2 | RCB 3 | Total | |
|---|---|---|---|---|---|
| Number of lesions | 9 (23.68%) | 7 (18.42%) | 14 (36.84%) | 8 (21.05%) | 38 (100%) |
| Age at diagnosis (years) | 53.22 (11.9) | 41.71 (12.73) | 52.33 (9.14) | 47.25 (9.13) | 49.47 (10.83) |
| Tumor type | |||||
| IDC | 8 (21.05%) | 7 (18.42%) | 13 (34.21%) | 8 (21.05%) | 36 (94.74%) |
| ILC | 1 (2.63%) | 0 (0.0%) | 1 (2.63%) | 0 (0.0%) | 2 (5.26%) |
| Histologic grade | |||||
| 1 | 0 (0.0%) | 0 (0.0%) | 1 (2.63%) | 0 (0.0%) | 1 (2.63%) |
| 2 | 1 (2.63%) | 3 (7.89%) | 3 (7.89%) | 3 (7.89%) | 10 (26.32%) |
| 3 | 8 (21.05%) | 4 (10.53%) | 10 (26.32%) | 5 (13.15%) | 27 (71.05%) |
| ER | |||||
| Positive | 3 (7.89%) | 5 (13.15%) | 7 (18.42%) | 6 (15.78%) | 21 (55.26%) |
| Negative | 6 (15.78%) | 2 (5.26%) | 7 (18.42%) | 2 (5.26%) | 17 (44.74%) |
| PR | |||||
| Positive | 0 (0.0%) | 4 (10.53%) | 8 (21.05%) | 5 (13.15%) | 17 (44.74%) |
| Negative | 9 (23.68%) | 3 (7.89%) | 6 (15.78%) | 3 (7.89%) | 21 (55.26%) |
| HER2 | |||||
| Positive | 4 (10.53%) | 2 (5.26%) | 6 (15.78%) | 2 (5.26%) | 14 (36.84%) |
| Negative | 5 (13.15%) | 5 (13.15%) | 8 (21.05%) | 6 (15.78%) | 24 (63.16%) |
| ER & PR | |||||
| Positive | 0 (0.0%) | 3 (7.89%) | 6 (15.78%) | 5 (13.15%) | 14 (36.84%) |
| TN | 4 (10.53%) | 1 (2.63%) | 3 (7.89%) | 1 (2.63%) | 9 (23.68%) |
| ki67 | |||||
| High (≥20%) | 9 (23.68%) | 6 (15.78%) | 11 (28.94%) | 4 (10.53%) | 30 (78.95%) |
| Low (20%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (5.26%) | 2 (5.26%) |
| N/A | 0 (0.0%) | 1 (2.63%) | 3 (7.89%) | 2 (5.26%) | 6 (15.79%) |
| Tumor diameter at baseline | Mean | ||||
| 22.55 (18.66) | 23.00 (13.27) | 36.64 (14.73) | 61.875 (27.50) | 36.10 (23.32) | |
Note: RCB, Residual Cancer Burden; ER, Estrogen Receptor; PR, Progesteron Receptor; HER2, Human Epidermal Growth Factor Receptor 2; TN, Triple negative (ER, PR, Her2 negative)